Current Applications of Liquid Chromatography/Mass Spectrometry in Pharmaceutical Discovery After a Decade of Innovation

被引:41
作者
Ackermann, Bradley L. [1 ]
Berna, Michael J. [1 ]
Eckstein, James A. [1 ]
Ott, Lee W. [1 ]
Chaudhary, Ajai K. [2 ]
机构
[1] Eli Lilly & Co, Greenfield Labs, Drug Disposit, Greenfield, IN 46140 USA
[2] Eli Lilly & Co, Lilly Corp Ctr, Drug Disposit, Indianapolis, IN 46285 USA
关键词
proteomics; metabonomics; biomarker; medicinal chemistry; bioanalytical; biotransformation;
D O I
10.1146/annurev.anchem.1.031207.112855
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Current drug discovery involves a highly iterative process pertaining to three core disciplines: biology, chemistry and drug disposition. For most pharmaceutical companies the path to a drug Candidate comprises similar stages: target identification, biological screening, lead generation, lead optimization, and candidate selection. Over the past decade, the overall efficiency of drug discovery has been greatly improved by a single instrumental technique, liquid chromatography/mass spectrometry (LC/MS). Transformed by the commercial introduction of the atmospheric pressure ionization interface ill the mid-1990s, LC/MS has expanded into almost every area of drug discovery. In many cases, drug discovery workflow has been changed owing to vastly improved efficiency. This review examines recent trends for these three core disciplines and presents seminal examples where LC/MS has altered the current approach to drug, discovery.
引用
收藏
页码:357 / 396
页数:40
相关论文
共 174 条
[1]   Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers [J].
Ackermann, Bradley L. ;
Berna, Michael J. .
EXPERT REVIEW OF PROTEOMICS, 2007, 4 (02) :175-186
[2]  
Ackermann BL, 2006, CURR DRUG METAB, V7, P525
[3]  
Ackermann BL, 2005, INTEGRATED STRATEGIES FOR DRUG DISCOVERY USING MASS SPECTROMETRY, P315, DOI 10.1002/0471721034.ch11
[4]   Development and application of a new on-line SPE system combined with LC-MS/MS detection for high throughput direct analysis of pharmaceutical compounds in plasma [J].
Alnouti, Y ;
Srinivasan, K ;
Waddell, D ;
Bi, HG ;
Kavetskaia, O ;
Gusev, AI .
JOURNAL OF CHROMATOGRAPHY A, 2005, 1080 (02) :99-106
[5]   Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins [J].
Anderson, L ;
Hunter, CL .
MOLECULAR & CELLULAR PROTEOMICS, 2006, 5 (04) :573-588
[6]   Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA) [J].
Anderson, NL ;
Anderson, NG ;
Haines, LR ;
Hardie, DB ;
Olafson, RW ;
Pearson, TW .
JOURNAL OF PROTEOME RESEARCH, 2004, 3 (02) :235-244
[7]  
[Anonymous], LG GC N AM
[8]  
[Anonymous], 2007, Introduction to mass spectrometry: Instrumentation, applications, and strategies for data interpretation
[9]   RCADiA: Simple automation platform for comparative multidimensional identification technology protein [J].
Bailey, Aaron O. ;
Miller, Timothy M. ;
Dong, Meng-Qiu ;
Velde, Christine Vande ;
Cleveland, Don W. ;
Yates, John R. .
ANALYTICAL CHEMISTRY, 2007, 79 (16) :6410-6418
[10]   Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry [J].
Balani, SK ;
Nagaraja, NV ;
Qian, MG ;
Costa, AO ;
Daniels, JS ;
Yang, H ;
Shimoga, PR ;
Wu, JT ;
Gan, LS ;
Lee, FW ;
Miwa, GT .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (03) :384-388